disease' versus 'exposure in patients with hepatic impairment There were no changes to suggest that olaparib causes liver injury, and there
Olaparib therapy is associated with a low rate of transient elevations in serum aminotransferase during therapy and has not been linked to instances of clinically apparent liver injury. Sections OVERVIEW
The PARP inhibitor olaparib (Lynparza) is a recently FDA-approved therapy for cancer. This study shows that PARP is overactivated in livers of subjects with alcoholic liver disease and that pharmacological inhibition of this enzyme with 3 different PARP inhibitors, including olaparib, attenuates high fat or alcohol induced liver injury, abnormal
Also, olaparib was not protecting the changes in MPO in liver and kidney. No effect of olaparib was noted on MDA concentrations in lung 7 d after injury. Olaparib also attenuated the increases in plasma markers of pancreatic and renal injury. It affected one liver injury marker (ALT) but not ALP. Limitations: [B], [C], [E], [I], and [J]. 84
Durvalumab, Placebo for Olaparib, Olaparib, Nab-paclitaxelcarboplatin Drug-induced liver injury1. participants affected / at risk, 2/401 (0.50%), 0
Challenges in PARP inhibitor therapy: A case of Olaparib-induced liver injury and successful rechallenge with Niraparib.
Olaparib; Oliceridine; Omaveloxolone; Omeprazole; Osimertinib; Ospemifene Liver diseaseUse with caution. May make these conditions worse. Kidney
Conversely, Rucaparib is extensively metabolized by cytochrome P450 enzymes and may be at high risk of cross reactivity in the setting of Olaparib-induced liver injury. Rechallenge with another PARPi after Olaparib-induced liver injury should carefully balance the potential clinical benefits against the risk of triggering severe hepatotoxicity.
Olaparib-Induced Immune-Mediated Liver Injury. Alshelleh M, Park J, John V, Rishi A, Bernstein D, Roth N ACG Case Rep J, 9(1):e
Comments